Shots: Aptar Pharma and Aceso Therapeutics have entered into a collaboration to advance ACT-101, an antisense oligonucleotide (ASO) candidate designed to target underlying disease mechanisms of cystic fibrosis (CF) Aptar Pharma’s specialist inhalation development services business; Nanopharm will lead formulation development and device assessment activities to support clinical development of ACT-101 The collaboration combines Nanopharm’s…